RMC-9945
RMC-9945 (RM-044) is a KRAS inhibitor and selective, covalent, orally active RAS(ON) G12D inhibitor. RMC-9945 increases β-Catenin/TCF transcriptional activity. RMC-9945 exerts durable disease control in preclinical colorectal cancer models of early liver metastasis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 2922732-38-3
- Fòrmula: C60H80F3N11O6S
- Peso molecular:1140.41
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
|
KRas G12D |
Chemical Information
-
No. CAS 2922732-38-3
-
Peso molecular 1140.41
-
Fòrmula C60H80F3N11O6S
-
SMILES
FC(F)(F)CN1[C@]([C@]2=C(N=CC(N3CCN(C4CC4)CC3)=C2)[C@H](C)OC)=C5C6=CC(C7=CSC(C[C@@H](C(N8N[C@](CCC8)([H])C(OCC(C)(C5)C)=O)=O)NC([C@@H](N9C[C@]%10(CN(CC%10)C([C@H]%11[C@@H](C%12CC%12)N%11C)=O)CC9)C(C)C)=O)=N7)=CC=C61
-
Synonyms
RM-044
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Centonze A, et al. A plastic EMP1⁺ to LGR5⁺ cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancer. Cancer Discov. 2025 Oct 21. [Content Brief]
[2]. Bu J, et al. Cancer Stem Cells in Human Gastrointestinal and Hepatic Cancers. MedComm (2020). 2025 Dec 3;6(12):e70513. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)